World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0020232995
Reproduction Date:

Title: 5-Iodowillardiine  
Author: World Heritage Encyclopedia
Language: English
Subject: MMPIP, LY-344,545, PEAQX, Tetrazolylglycine, EGLU
Publisher: World Heritage Encyclopedia


CAS number  N
ChemSpider  YesY
Jmol-3D images Image 1
Image 2
Molecular formula C7H8IN3O4
Molar mass 325.06 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N   YesY/N?)

5-Iodowillardiine is a selective agonist for the kainate receptor, with only limited effects at the AMPA receptor.[1] It is selective for kainate receptors composed of GluR5 subunits.[2][3] It is an excitotoxic neurotoxin in vivo,[4][5] but has proved highly useful for characterising the subtypes and function of the various kainate receptors in the brain and spinal cord.[6][7][8]


  1. ^ Patneau, DK; Mayer, ML; Jane, DE; Watkins, JC (1992). "Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine". Journal of Neuroscience 12 (2): 595–606.  
  2. ^ Swanson, GT; Green, T; Heinemann, SF (1998). "Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine". Molecular Pharmacology 53 (5): 942–9.  
  3. ^ Cui, C; Mayer, ML (1999). "Heteromeric kainate receptors formed by the coassembly of GluR5, GluR6, and GluR7". Journal of Neuroscience 19 (19): 8281–91.  
  4. ^ Moldrich, RX; Cheung, NS; Pascoe, CJ; Beart, PM (1999). "Excitotoxic injury profiles of low-affinity kainate receptor agonists in cortical neuronal cultures". European Journal of Pharmacology 378 (2): R1–3.  
  5. ^ Moldrich, RX; Beart, PM; Pascoe, CJ; Cheung, NS (2000). "Low-affinity kainate receptor agonists induce insult-dependent apoptosis and necrosis in cultured murine cortical neurons". Journal of neuroscience research 59 (6): 788–96.  
  6. ^ Mascias, P; Scheede, M; Bloms-Funke, P; Chizh, B (2002). "Modulation of spinal nociception by GluR5 kainate receptor ligands in acute and hyperalgesic states and the role of gabaergic mechanisms". Neuropharmacology 43 (3): 327–39.  
  7. ^ Alt, A; Weiss, B; Ogden, AM; Knauss, JL; Oler, J; Ho, K; Large, TH; Bleakman, D (2004). "Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro". Neuropharmacology 46 (6): 793–806.  
  8. ^ Jane, DE; Lodge, D; Collingridge, GL (2009). "Kainate receptors: pharmacology, function and therapeutic potential". Neuropharmacology 56 (1): 90–113.  

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.